nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.06.2023 | Editorial

Why does PSMA PET improve quality of life?

verfasst von: Laura Evangelista, Joshua James Morigi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Excerpt

Radiolabeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has completely changed the diagnostic approach for patients affected by prostate cancer (PCa). The available evidence, indeed, demonstrates a strong impact of this imaging modality in different settings of the disease, from diagnosis to the restaging phase [1, 2]. …

Yip KCJ, Li YL, Chen S, et al. 68Ga-PSMA PET/CT and mpMRI for primary lymph node staging of intermediate to high-risk prostate cancer: a systematic review and meta-analysis of diagnostic test accuracy. Clin Transl Imaging. 2021;9:523–37.CrossRef

Liu A, Chen L, Zhang M, et al. Impact of PSMA PET on management of biochemical recurrent prostate cancer: a systematic review and meta-analysis of prospective studies. Clin Transl Imaging. 2021;9:95–108.CrossRef

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2017;44:81–91.CrossRefPubMed

Marinova M, Alamdar R, Ahmadzadehfar H, Essler M, Attenberger U, Mücke M, Conrad R. Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. Nuklearmedizin. 2020;59:409–14.CrossRefPubMed

Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:597–610.CrossRefPubMed

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG, proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.CrossRefPubMed

Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682–9.CrossRefPubMed

van der Sar ECA, Keusters WR, van Kalmthout LWM, Braat AJAT, de Keizer B, Frederix GWJ, Kooistra A, Lavalaye J, Lam MGEH, van Melick HHE. Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging. Insights Imaging. 2022;13:132.CrossRefPubMedPubMedCentral

Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626–38.CrossRefPubMedPubMedCentral

10.

Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405–12.CrossRefPubMed

11.

Ma W, Mao J, Yang J, Wang T, Zhao ZH. Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis. Eur Radiol. 2022;32:7374–85.CrossRefPubMedPubMedCentral

12.

Ceci F, Rovera G, Iorio GC, et al. Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022;49:3257–68.CrossRefPubMedPubMedCentral

13.

Bowden P, See AW, So K, Lawrentschuk N, Moon D, Murphy DG, Rao R, Crosthwaite A, King D, Haxhimolla H, Grummet J, Ruljancich P, Gyomber D, Landau A, Campbell N, Frydenberg M, Smyth LML, Nolan S, Gwini SM, McKenzie DP. 68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial. World J Urol. 2021;39:4117–25.CrossRefPubMedPubMedCentral

14.

Lucchini R, Franzese C, Vukcaj S, Purrello G, Panizza D, Faccenda V, Andreoli S, Poli GL, Baldaccini D, Lo Faro L, Tomatis S, Cazzaniga LF, Scorsetti M, Arcangeli S. Acute toxicity and quality of life in a post-prostatectomy ablative radiation therapy (POPART) multicentric trial. Curr Oncol. 2022;29:9349–56.CrossRefPubMedPubMedCentral

15.

Greco C, Pares O, Pimentel N, Louro V, Nunes B, Kociolek J, Marques J, Fuks Z. Health-related quality of life of salvage prostate reirradiation using stereotactic ablative radiotherapy with urethral-sparing. Front Oncol. 2022;12: 984917.CrossRefPubMedPubMedCentral

16.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. 68Ga-PSMA-11 PET/CT Mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–7.CrossRefPubMedPubMedCentral

17.

Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2018;74:179–90.CrossRefPubMed

18.

Tucci M, Leone G, Buttigliero C, Zichi C, Di Stefano RF, Pignataro D, Vignani F, Scagliotti GV, Di Maio M. Hormonal treatment and quality of life of prostate cancer patients: new evidence. Minerva Urol Nefrol. 2018;70:144–51.PubMed

19.

Lilleby W, Stensvold A, Dahl AA. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer. Acta Oncol. 2016;55:807–13.CrossRefPubMed

20.

Bobrowski A, Metser U, Finelli A, Fleshner N, Berlin A, Perlis N, Kulkarni GS, Chung P, Kuhathaas K, Atenafu EG, Hamilton RJ. Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Can Urol Assoc J. 2021;15:E545–52.CrossRefPubMedPubMedCentral

21.

Galgano SJ, McDonald AM, West JT, Rais-Bahrami S. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022;14:3302.CrossRefPubMed

Titel: Why does PSMA PET improve quality of life?
verfasst von: Laura Evangelista
Joshua James Morigi
Publikationsdatum: 23.06.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06307-z

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Why does PSMA PET improve quality of life?

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome

[18F]FDG PET/CT advanced imaging in crucial management steps of a child affected by hypoplastic left heart syndrome

Superiority of [68Ga]Ga-DOTA-FAPI-04 PET/CT to [18F]FDG PET/CT in the evaluation of thymic epithelial tumours

[18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma

Not all black colons on [18F]FDG PET are due to metformin

SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T